Generation Bio Co. (GBIO)

NASDAQ: GBIO · IEX Real-Time Price · USD
2.960
-0.130 (-4.21%)
At close: Mar 18, 2024, 4:00 PM
2.890
-0.070 (-2.36%)
After-hours: Mar 18, 2024, 5:39 PM EDT
-4.21%
Market Cap 203.42M
Revenue (ttm) 5.90M
Net Income (ttm) -126.61M
Shares Out 66.48M
EPS (ttm) -1.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 138,800
Open 3.110
Previous Close 3.090
Day's Range 2.946 - 3.110
52-Week Range 0.860 - 6.980
Beta 2.70
Analysts Buy
Price Target 8.00 (+170.27%)
Earnings Date Mar 6, 2024

About GBIO

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating epi... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 12, 2020
Employees 174
Stock Exchange NASDAQ
Ticker Symbol GBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for GBIO stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 170.27% from the latest price.

Price Target
$8.0
(170.27% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

- Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia

12 days ago - GlobeNewsWire

Generation Bio to Present at the 2024 TD Cowen Health Care Conference

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced ...

20 days ago - GlobeNewsWire

Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced ...

2 months ago - GlobeNewsWire

Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms

CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced...

3 months ago - GlobeNewsWire

Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results

-  Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics

4 months ago - GlobeNewsWire

Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform

CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced...

5 months ago - GlobeNewsWire

Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: EVLOSPRB
5 months ago - Benzinga

Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA

– Immune-quiet DNA (iqDNA) is a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection in both mice and non-human primates (NHPs) with a systemic cytokine profile and toler...

5 months ago - GlobeNewsWire

Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit

CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...

6 months ago - GlobeNewsWire

Generation Bio to Present at the Canaccord Genuity 43rd Annual Growth Conference

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced...

8 months ago - GlobeNewsWire

Generation Bio Reports Second Quarter 2023 Financial Results

Second quarter 2023 cash balance of $314.1 million expected to fund operations into 2025 Second quarter 2023 cash balance of $314.1 million expected to fund operations into 2025

8 months ago - GlobeNewsWire

Generation Bio to Present at the 2023 Jefferies Healthcare Conference

CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced ...

10 months ago - GlobeNewsWire

Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results

Company entered into strategic collaboration with Moderna to use Generation Bio's proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targetin...

11 months ago - GlobeNewsWire

Generation Bio to Present at the JMP Securities Life Sciences Conference

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced ...

11 months ago - GlobeNewsWire

Generation Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...

1 year ago - GlobeNewsWire

Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer

CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...

1 year ago - GlobeNewsWire

Generation Bio, Moderna announce collaboration

Shares of Generation Bio Co. GBIO, -0.51% jumped about 28% premarket trading on Thursday after the company announced a collaboration with Moderna Inc. MRNA, -2.58% to to develop novel nucleic acid the...

Other symbols: MRNA
1 year ago - Market Watch

Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines

Collaboration will extend the applications of each company's platform through discovery and development of novel lipid nanoparticles using Generation Bio's proprietary stealth cell-targeted lipid nano...

Other symbols: MRNA
1 year ago - Accesswire

Generation Bio to Participate in the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...

1 year ago - GlobeNewsWire

Generation Bio to Present at the 43rd Annual Cowen Healthcare Conference

CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced...

1 year ago - GlobeNewsWire

Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results

— Company expects to announce data for Factor VIII expression in non-human primates in 2023

1 year ago - GlobeNewsWire

Generation Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...

1 year ago - GlobeNewsWire

Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results

Cash balance of $301.2M expected to fund operations into 2025 Cash balance of $301.2M expected to fund operations into 2025

1 year ago - GlobeNewsWire

Generation Bio to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announc...

1 year ago - GlobeNewsWire

Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer

CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announc...

1 year ago - GlobeNewsWire